Cogentix Medical
Minnesota City · Founded 1987
About Cogentix Medical
Cogentix Medical products have increased treatment efficiency and lowered patient risk. Macroplastique® established the European market for bulking agents, EndoSheath® protective barrier redefined endoscopy and Urgent® PC set the standard for percutaneous tibial nerve stimulation (PTNS) as a treatment for Overactive Bladder. Cogentix Medical was formed in 2015 following a merger of Uroplasty and Vision-Sciences.
Company Facts
- Founded: 1987
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $25.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2016)
- Ticker: nasdaq:CGNT
- Website: cogentixmedical.com
- Phone: +118662582182
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cogentix-medical-2214155 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.